Comparison of biologic monotherapy versus biologic and disease-modifying anti-rheumatic drug combination in the treatment of non-systemic juvenile idiopathic arthritis

Authors : Fatma Gül DEMİRKAN, Nuray AKTAY AYAZ

Pages : 406-411

Doi:10.12956/tchd.1345189

View : 64 | Download : 37

Publication Date : 2023-09-25

Article Type : Research Paper

Abstract :Purpose To explore the efficacy of biologics as mono- or combination therapy with conventional disease modifying anti-rheumatic drugs insert ignore into journalissuearticles values(cDMARDs); in the treatment of juvenile idiopathic arthritis insert ignore into journalissuearticles values(JIA);. Material and Methods Medical records of patients with JIA followed-up from January 2020 to 2023 who were treated either with biologic drugs as monotherapy or with combination of cDMARD were reviewed retrospectively. Data of demographic features, clinical scores and treatments were assessed. Results Two hundred five cases received etanercept, adalimumab, or tocilizumab alone or in combination with a cDMARD for JIA were included. The male to female ratio of the cohort was almost equal. Oligoarticular was the most common subtype of JIA. Majority insert ignore into journalissuearticles values(n=128, 62.4%); of the group received biologic drugs as monotherapy, while the remaining third insert ignore into journalissuearticles values(n=77, 37.6%); used a combination of biologic and a cDMARD. Nearly half of the group insert ignore into journalissuearticles values(57.1%); were treated with etanercept and etanercept monotherapy was the most commonly used one among all JIA subtypes except juvenile psoriatic arthritis. Adalimumab combination therapy was prescribed in most of the children with juvenile psoriatic arthritis. Adalimumab, alone or in combination with methotrexate, was preferred for all 8 patients with uveitis at the onset of the disease. Adalimumab combined insert ignore into journalissuearticles values(n=9); and tocilizumab monotherapy insert ignore into journalissuearticles values(n=4); were the most common biologics in those who developed uveitis during follow-up. Conclusion Etanercept, adalimumab, or tocilizumab are effective and safe biologics in treatment of JIA. Considering their cost-effective properties, choosing biologic drugs timely as combined or monotherapy is effective in preventing early and late sequelae of JIA.
Keywords : Juvenil idiyopatik artrit, biyolojik ilaç, hastalık modifiye edici anti romatizmal ilaçlar

ORIGINAL ARTICLE URL